CBmed GmbH

R&D Institution

About

CBmed is an independent publicly owned biomedical research center based in Graz, Austria, dedicated to enabling applied precision medicine through translational research. Founded in 2014, CBmed operates at the interface of academic discovery, clinical research and industry collaboration, with a strong focus on patient-relevant impact.

CBmed combines state-of-the-art research infrastructure, deep disease biology expertise, and direct access to large-scale clinical and biobank resources, including Europe’s largest biobank (Biobank Graz) and the BBMRI‑ERIC network. This unique positioning enables robust biomarker discovery, validation, and translation across diverse health domains.

Core capabilities include multi‑omics integration, data science and clinical decision support, patient‑derived ex‑vivo disease models, microbiome research, and high‑quality laboratory and data workflows supported by Total Quality Management and advanced laboratory management systems. These modular platforms are designed to support complex, multi-partner projects from early discovery through translational proof‑of‑concept.

With a decade of experience in national and international collaborative research, CBmed is a consortium‑ready partner in Horizon Europe Cluster Health projects, contributing validated infrastructure, translational expertise, and governance experience to interdisciplinary, impact‑driven consortia.

Representatives

Head of Public Funding

CBmed GmbH

Marketplace (4)

Project cooperation
Microbiome research in health and disease
CBmed offers translational microbiome research, integrating clinical biosamples, functional host–microbiome analysis, and patient‑derived microbiome modulation platforms to support biomarker discovery and intervention strategies in health research.
Partner seeks Consortium/Coordinator
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Author
Head of Public Funding at CBmed GmbH
Graz, Austria
Project cooperation
Ex Vivo Compound Screening and Drug Repurposing
CBmed offers automated ex vivo compound screening combining high‑throughput and high‑content readouts in 384‑well formats, including screening of patient‑derived tumor cells (2D/3D) to support precision medicine and translational drug development.
Partner seeks Consortium/Coordinator
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Author
Head of Public Funding at CBmed GmbH
Graz, Austria
Project cooperation
Diabetes Research (β‑cell stress, biomarkers & therapy advancement)
CBmed advances diabetes research by identifying biomarkers and repurposing approved drugs to alleviate cellular stress and protect pancreatic β‑cells, using state‑of‑the‑art in vitro/in vivo models to study β‑cell stress and immunity across T1D and T2D.
Author
Head of Public Funding at CBmed GmbH
Graz, Austria
Project cooperation
Core Technologies for Precision Medicine
CBmed offers integrated core technologies for precision medicine, combining advanced immunology wet labs, 2D/3D cell culture, imaging, ex vivo screening and data science to support high‑quality, reproducible translational health research.
Author
Head of Public Funding at CBmed GmbH
Graz, Austria